Reversible severe synovitis associated with everolimus.
Kato
Tomoko S
TS
Sasaoka
Taro
T
Wada
Kyoichi
K
Nakatani
Takeshi
T
Komamura
Kazuo
K
D000328:Adult; D000068338:Everolimus; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors; D008297:Male; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D012720:Severity of Illness Index; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D013585:Synovitis / Q000139:chemically induced* / Q000503:physiopathology*; D058570:TOR Serine-Threonine Kinases; D028761:Withholding Treatment
D007166:Immunosuppressive Agents; D047908:Intracellular Signaling Peptides and Proteins; D000068338:Everolimus; C546842:MTOR protein, human; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus